- General
- June 9, 2018
- 2 minutes read
Vaccine company SutroVax raises $85 Million Series C to fuel expansion
image credit : SutroVax SutroVax, A 5 year old Sutro Biopharma spin-off company has raised a recent investment of a quite…
image credit : SutroVax
SutroVax, A 5 year old Sutro Biopharma spin-off company has raised a recent investment of a quite huge amount of $85 million in a round led by notable investor TPG to fund its expansion and advancement of the company and its pneumococcal vaccine for use by the consumers.
Other companies including Pharmaceutical giant Roche, Pivotal bioVenture Partners and London based VC firm Abingworth who are also previous investors in the company also participated in this round.
The company has now raised a huge figure of $175 million in total to further its mission advancing its pneumococcal conjugate vaccine and other novel vaccines for efficient use by many.
The company is also adding GSK former R & D head and SutroVax independent board member Moncef Slaoui as its board chairman, A move which also collerates with the fact that Slaoui has a very wide and long experience in the biotech field and will greatly use this knowledge to vastly improve the company’s prospects.
TPG partner Heath Lukatch will also be joining the board along with Francesco de Rubertis who is a founding partner of Medicxi Venture Capital where Moncef Slaoui is also a partner.
